Celixir plc products

PHASE 2 : Our first investigational cardiac regenerative medicine consists of iMP cells. iMP cells are designed to treat patients with ischaemic heart disease – ischaemic cardiomyopathy – undergoing coronary artery bypass graft (CABG). They are injected around cardiac scar tissue via a single application during bypass surgery.

PHASE 3 : Our investigational topical gel containing platelet lysate is capable of regenerating injured tendons near the surface of the skin.

Clinical trial ready : PML cells are being investigated as a treatment for patients with mild to moderate heart failure.